TLR9 and STING agonists synergistically induce innate and adaptive type‐II IFN

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: TLR9 and STING agonists synergistically induce innate and adaptive type‐II IFN ; volume:45 ; number:4 ; year:2015 ; pages:1159-1169 ; extent:11
European journal of immunology ; 45, Heft 4 (2015), 1159-1169 (gesamt 11)

Creator: Temizoz, Burcu
Kuroda, Etsushi
Ohata, Keiichi
Jounai, Nao
Ozasa, Koji
Kobiyama, Kouji
Aoshi, Taiki
Ishii, Ken J.

DOI: 10.1002/eji.201445132

URN: urn:nbn:de:101:1-2022112507103068356184

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:25 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Temizoz, Burcu
Kuroda, Etsushi
Ohata, Keiichi
Jounai, Nao
Ozasa, Koji
Kobiyama, Kouji
Aoshi, Taiki
Ishii, Ken J.

Other Objects (12)

Prediction of novel mouse TLR9 agonists using a random forest approach

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists

Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy

MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

Prediction of novel mouse TLR9 agonists using a random forest approach

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists

Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy

MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

Prediction of novel mouse TLR9 agonists using a random forest approach

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists

Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy

MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

TLR9 and STING agonists synergistically induce innate and adaptive type‐II IFN

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Prediction of novel mouse TLR9 agonists using a random forest approach

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists

Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy

MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

Prediction of novel mouse TLR9 agonists using a random forest approach

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists

Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy

MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

Prediction of novel mouse TLR9 agonists using a random forest approach

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists

Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy

MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

Related objects

Reset password